Cryptic Proteins Interfere With Influenza Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for addressing influenza virus replication are hindered by the high error rates of viral RNA-dependent RNA polymerases, which introduce mutations and defective viral genomes that interfere with wild-type virus replication, and the mechanisms of this interference are not fully understood.
Innovation Solution
Development of modified influenza gene products, including recombinant viruses with defective viral genomes that encode inhibitory proteins, which can interfere with viral replication by competing with wild-type polymerase assembly and replication, providing a dual mechanism of action as both RNA and protein-based inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral RNA-dependent RNA polymerase is used to replicate viral genomes, then rapid replication is achieved, but high error rates and defective viral genomes are introduced
Solution Approach 1:
The patent converts the harmful defective viral genomes (DVGs) produced by the error-prone polymerase into beneficial therapeutic agents. DVGs are engineered to encode dominant-negative proteins that specifically inhibit wild-type virus replication, transforming a replication byproduct into a targeted antiviral mechanism that exploits the virus's own replication machinery against it
2Object-affected harmful factors
If defective viral genomes are used to inhibit wild-type virus replication, then antiviral activity is achieved, but the mechanism of interference is not fully understood
Solution Approach 1:
The patent introduces DVG-encoded proteins as intermediary agents that mediate the inhibition of wild-type virus replication. These proteins act as dominant-negative inhibitors that specifically target and block the function of wild-type viral proteins, providing a measurable and characterizable mechanism of action that bridges the gap between DVG presence and antiviral effect
3Adaptability or versatility
If recombinant viruses with defective viral genomes are developed, then dual mechanism of action (RNA and protein inhibitors) is achieved, but increased complexity in virus construction is required
Solution Approach 1:
The patent merges two inhibitory mechanisms into a single recombinant viral construct: the DVG RNA itself acts as a parasitic element competing for replication resources, while simultaneously encoding dominant-negative proteins that directly inhibit wild-type virus function. This combination creates a synergistic dual-action antiviral agent from a single engineered viral genome
Data Source
AI summary
The disclosure provides for methods for making and using modified influenza gene products, alone or in combination, e.g., to inhibit wild-type influenza virus replication, to serve as an immunostimulatory agent, and/or as attenuated vaccine backbones. In one embodiment, the genomes of the DIPs provide for inhibitory activity, producing a dual effect in which both the RNA itself and the encoded protein coordinate to interfere with replication. Thus, the ability of DIPs to block replication of WT virus provides for a treatment for infection, use as an immunostimulatory agent, and as attenuated viruses for vaccination.